Can a New Dietary Supplement Help Minimise the Risk of Breast Cancer?
In the UK, about 1 in 8 women will develop breast cancer at some point during their lifetime. While there is no guaranteed way to prevent the disease, there are steps that may help lower the risk — especially for those at an increased risk of developing breast cancer.
As well as leading a healthy diet and lifestyle, women who are at risk or worried about breast cancer may be able to lower their chances of developing it, by supplementing their diet with a revolutionary new supplement, ProfBiotics Breast. Welcomed by leading cancer experts, it has been developed in consultation with Professor Martyn Caplin, leading cancer specialist and consultant gastroenterologist at London’s Royal Free Hospital, following a comprehensive review of clinical evidence investigating the role of specific nutrients in breast cancer prevention.
The supplement has been formulated to contain the specific blend of ingredients to help support breast wellbeing:
• Lycopene (tomato powder 5 mg), which has been increasingly associated with breast well-being. Studies suggest that women with higher circulating levels of lycopene may be at reduced risk of breast cancer
• Vitamin D (12.5 mcg [500 IU]), which has been found to regulate cell death – data suggest there is an association between lower levels of vitamin D and higher rates of breast cancer
• Zinc ([from Citrate] 7.5mg) — studies find that low zinc intake may be linked to breast cancer risk
• Curcumin (extract 25:1 — 240 mg providing 6000 mg whole herb equivalent) , which appears to be useful in preventing human breast cancer development.
The formula contains the equivalent of eight teaspoons of turmeric which would be difficult to consume each day through diet alone.
Cancer experts have welcomed the initiative. Justin Stebbing, Professor of Cancer Medicine and Oncology at Imperial College London, comments, “Any approach which may help reduce cancer risk utilising diet and appropriate nutrients is of huge potential value for individuals and society. The combinations used in these products are in line with the results of scientific research studying different tumour types and represent a new approach to tackling cancer incidence through diet and nutrient supplementation. The formulations may also have a role during and after cancer treatment for nutritional support, and to counter adverse effects of chemotherapies.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance